Details of the Drug-Related molecule(s) Interaction Atlas
General Information of Drug (ID: DMB0OZ3)
| Drug Name | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
947303-87-9; PF-429242; (R)-4-((Diethylamino)methyl)-N-(2-methoxyphenethyl)-N-(pyrrolidin-3-yl)benzamide; UNII-49WB3OA7VN; 49WB3OA7VN; PF 429242; PF429242; CHEMBL233611; J-502224; C25H35N3O2; 4-[(Diethylamino)methyl]-N-[2-(2-methoxyphenyl)ethyl]-N-(3R)-3-pyrrolidinylbenzamide; (R)-4-((Diethylamino)methyl)-N-(2-methoxyphenethyl)-N-(pyrrolidin-3-yl)benz amide; (-)-PF-429242; SCHEMBL2742702; CTK8B5018; DTXSID00635376; EX-A1409; ANW-47048; ZINC28823615; BDBM50216181; AKOS015998619; RL05965; Benzamide, 4-((diethylamino)methyl)-N-(2-(
|
|||||||||||||||||||
| Indication |
|
|||||||||||||||||||
| Cross-matching ID | ||||||||||||||||||||
Molecule-Related Drug Atlas
|
Molecule-Related Drug Atlas
Molecule Type:
DTT DOT Drug Status:
Approved Drug(s) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Drug(s) Affected By Stearoyl-CoA desaturase (SCD)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Drug(s) Affected By Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
| Molecular Interaction Atlas | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
![]() Drug Off-Target (DOT) |
|
|||||||||||||||||||||||||||||||
References


